Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR236553 (REGN727) in heterozygous familial hypercholesterolemia not adequately controlled with lipid-modifying therapy
2011-005109-56Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jul 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in familial hypercholesterolemia (FH) comparing SAR236553 with Placebo (2 arms). Primary endpoint: Percent change in LDL-C at 24 weeks. Started Jul 2012; status: completed.
02
Drugs
alirocumab
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on 2011-005109-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005109-56.